Get the Stockscreener App
4.53
1.34%
0.06
Y Mabs Therapeutics Inc stock is traded at $4.53, with a volume of 138.79K.
It is up +1.34% in the last 24 hours and up +2.72% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$4.47
Open:
$4.4
24h Volume:
138.79K
Relative Volume:
0.71
Market Cap:
$205.19M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-9.2449
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-5.03%
1M Performance:
+2.72%
6M Performance:
-24.12%
1Y Performance:
-61.08%
1-Day Range:
$4.2908
$4.585
1-Week Range:
$4.2908
$5.18
52-Week Range:
$3.55
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.53 | 202.47M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Grows By 80,222.6% - Defense World
Y mAbs Therapeutics Inc. stock trendline breakdownFree Investment Playbook for Growing Markets - Newser
Chart based analysis of Y mAbs Therapeutics Inc. trendsFree Consistent Profit Pattern Recognition Tools - Newser
Measuring Y mAbs Therapeutics Inc.’s beta against major indicesSmart Stock Forecast Using AI Algorithms - Newser
Why Y mAbs Therapeutics Inc. stock attracts strong analyst attentionTrade Flow Monitor with Volume Tracker - Newser
What are the latest earnings results for Y mAbs Therapeutics Inc.Stock Strategy Trend Scanner To Watch Now - jammulinksnews.com
Why is Y mAbs Therapeutics Inc. stock attracting strong analyst attentionBreakout Stocks Strategy With Low Risk - jammulinksnews.com
New Product Launches: Will They Boost Y mAbs Therapeutics Inc. Stock in 2025Free Swing Trading Plan With Smart Signals - Newser
Combining price and volume data for Y mAbs Therapeutics Inc.AI Generated Momentum Stock Forecast Guide - Newser
How Efficient Is Y mAbs Therapeutics Inc. at Controlling Operating CostsEarly Entry Planner for Swing Candidates - Newser
Bollinger Bands Expand on Y mAbs Therapeutics Inc. — Volatility AheadSecure Return Focused Investment Plan Released - metal.it
Published on: 2025-07-30 07:01:10 - metal.it
Published on: 2025-07-30 02:35:10 - metal.it
Published on: 2025-07-29 20:52:52 - metal.it
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
What makes Y mAbs Therapeutics Inc. stock price move sharplyInvestment Life Cycle Planning Summary - Newser
What institutional investors are buying Y mAbs Therapeutics Inc. stockPost Market Opportunities With High Returns - jammulinksnews.com
Does Y mAbs Therapeutics Inc. stock perform well during market downturnsFree Market Volatility Navigation Tips - jammulinksnews.com
What catalysts could drive Y mAbs Therapeutics Inc. stock higher in 2025Unlock daily market insights for better decisions - jammulinksnews.com
How does Y mAbs Therapeutics Inc. compare to its industry peersMaximize your returns with portfolio optimization - jammulinksnews.com
Y mAbs Therapeutics Inc. Company Revenue and Profit Trends: A Deep DiveFree Predictions - metal.it
What is Y mAbs Therapeutics Inc. company’s growth strategyUnlock exclusive trading strategies for gains - jammulinksnews.com
What are Y mAbs Therapeutics Inc. company’s key revenue driversGet ahead with breakthrough trading ideas - jammulinksnews.com
Should I hold or sell Y mAbs Therapeutics Inc. stock in 2025Free High-Return Strategy Alerts - jammulinksnews.com
How strong is Y mAbs Therapeutics Inc. company’s balance sheetMaximize your portfolio’s earning potential - jammulinksnews.com
What drives Y mAbs Therapeutics Inc. stock priceFree Stock Market Beginners Guide - PrintWeekIndia
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
Will Y mAbs Therapeutics Inc. stock split in the near futureOutperformance with explosive growth - jammulinksnews.com
What analysts say about Y mAbs Therapeutics Inc. stockFree Predictions - PrintWeekIndia
Will Y mAbs Therapeutics Inc. stock benefit from AI tech trendsHigh-profit capital plays - jammulinksnews.com
Should I buy Y mAbs Therapeutics Inc. stock before earningsFree Predictions - jammulinksnews.com
Following a 61% decline over last year, recent gains may please Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) institutional owners - simplywall.st
How the (YMAB) price action is used to our Advantage - news.stocktradersdaily.com
Is Y mAbs Therapeutics Inc. a good long term investmentMarket-beating performance - jammulinksnews.com
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rossi Michael J | PRESIDENT & CEO |
Mar 07 '25 |
Sale |
5.20 |
3,917 |
20,368 |
137,083 |
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):